Status:
COMPLETED
Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer
Lead Sponsor:
University of Leipzig
Collaborating Sponsors:
German Federal Ministry of Education and Research
Conditions:
Esophageal Neoplasms
Stomach Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to identify biomarkers predicting response or resistance factors of a targeted therapy with trastuzumab in advanced gastric cancer.
Eligibility Criteria
Inclusion
- histologically proven adenocarcinoma of the stomach or gastroesophageal junction
- stage IV
- patient receives chemotherapy
- signed informed consent
- Age \> 18 years
Exclusion
- Patient can not understand meaning and purpose of the study
- patient already received a chemotherapy treatment for advanced disease.
Key Trial Info
Start Date :
March 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2018
Estimated Enrollment :
549 Patients enrolled
Trial Details
Trial ID
NCT02305043
Start Date
March 1 2014
End Date
January 31 2018
Last Update
July 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Cancer Center Leipzig
Leipzig, Germany, 04103